Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention provides a new use of a D3 antagonist of formula (I), as disclosed in the International Patent Application WO 2005/08032, in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome
• a somatoform disorder such as body dysmorph
• the DSM-IV sets forth two indicia of compulsion.
• the person has repetitive behaviors or mental acts that the person feels driven to perform in response to an obsession or according to rules that must be applied rigidly. Repetitive behaviors include hand washing, ordering and checking, while mental acts include voting, counting and repeating words silently.
• the behaviors or mental acts are aimed at preventing some dreaded event or situation; however, these behaviors or mental acts either are not connected in a realistic way to what they are designed to neutralize or prevent, or are clearly excessive.
• Y-BOCS Yale-Brown Obsessive-Compulsive Scale
• Obsessive-compulsive spectrum disorders include somatoform disorders including body dysmorphic disorder and hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, and movement disorders, including Tourette's syndrome.
• Somatoform disorders include body dysmorphic disorder (BDD) and hyperchondriasis.
• Body dysmorphic disorder (BDD) is a preoccupation with an imagined slight defect in appearance that causes significant distress or impairment in functioning.
• Individuals suffering from BDD have preoccupations similar to OCD obsessions in that they have repetitive intrusive thoughts, often perform time-consuming, repetitive and sometimes ritualistic behaviours.
• Hypochondriasis is a preoccupation with the fear of having, or the idea that one has, a serious disease based on the person's misinterpretation of bodily signs or symptoms.
• Hypochondriacal preoccupations resemble OCD obsessions in that they are often experienced as intrusive and persistent, and the individuals often display repetitive checking behaviours.
• the DSM-IV defines anorexia nervosa as a refusal to maintain a minimally normal body weight; intensive fear of gaining weight or becoming fat even though underweight; significant disturbance in perception of body shape or size; and, in females, amenorrhea.
• the DSM- IV defines bulimia nervosa as recurrent episodes of binge eating followed by inappropriate compensatory behaviours designed to prevent a weight gain.
• BED is characterized by recurrent episodes of binge eating in the absence of regular use of inappropriate compensatory behaviours.
• all three disorders are characterized by a core preoccupation with food and body weight. Individuals suffering from these disorders often perform specific rituals, and have an abnormal preoccupation with food and weight.
• NPSAs nonparaphilic sexual addictions
• Tourette's syndrome is a chronic neuropsychiatric disorder characterized by motor tics and one or more vocal tics beginning before the age of 18 years.
• the DSM-IV defines a tic as a sudden, rapid, recurrent, nonrhythmic, stereotyped motor movement or vocalization.
• Tourette's syndrome patients may be able to suppress tics for varying lengths of time, but eventually experience them as irresistible and perform them.
• Tourette's patients exhibit obsessions resembling OCD obsessions, for example, they often feel the need to perform tics until they are felt to be "just right.”
• Autism is characterized by difficulties with social interaction, speech and communication, and by a compulsive core. Autistic individuals often display compulsive, repetitive behaviors.
• the present invention provides a new use of a D3 antagonist in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervo
• a D3 antagonist for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
• this invention provides a method of treating a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; or premature ejaculation, comprising administering to a mammal in need thereof an effective amount of a D3 antagonist.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; or premature ejaculation
• the present invention provides a new use of a D3 antagonist in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervo
• a D3 antagonist for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
• this invention provides a method of treating a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and a method of treating premature ejaculation, comprising administering to a mammal in need thereof an effective amount of a D3 antagonist.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome.
• Treatment includes prophylaxis, where this is appropriate for the relevant condition(s).
• the present invention provides a new use of compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
• G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R 1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloCi. 4 alkyl, C 1 ⁇ aIkOXy, haloC ⁇ alkoxy, C ⁇ alkanoyl; or corresponds to a group R 5 ; R 2 is hydrogen or C 1-4 alkyl;
• R 3 is C 1-4 alkyl
• R 4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl;
• R 5 is a moiety selected from the group consisting of: isoxazolyl, -CH 2 -N- pyrrolyl, 1 ,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2- pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, d ⁇ alkyl, haloC 1-4 alkyl, C 1- 4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R 1 corresponds to R 5 , p is 1 ; in the manufacture of a medicament for the treatment of of of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervo
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above or premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) as herein defined or a salt thereof.
• a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the treatment of premature ejaculation.
• the somatoform disorder is binge eating.
• Treatment includes prophylaxis, where this is appropriate for the relevant condition(s).
• G 1 p, R 1 , R 2 , R 3 , R 4 , and R 5 are defined as above for compounds of formula (I), in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above; and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I)' as herein defined or a salt thereof.
• the somatoform disorder is binge eating.
• G, p, R 1 , R 2 , R 3 , R 4 , and R 5 are defined as above for compounds of formula (I)' or a salt thereof, in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IA) as herein defined or a salt thereof.
• the somatoform disorder is binge eating.
• stereochemical isomers enriched in configuration (1 S.5R) or (1 R.5R) of formula (IA) correspond in one embodiment to at least 90% e.e. In another embodiment the isomers correspond to at least 95% e.e. In another embodiment the isomers correspond to at least 99% e.e.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
• a still further aspect of the invention provides a method of treating a somatoform disoder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound from the list cited above or a salt thereof.
• a mammal e.g. human
• the somatoform disorder is binge eating.
• 5- or 6-membered heteroaromatic group refers to a monocyclic 5- or 6- membered heterocyclic group containing 1 , 2, 3 or 4 heteroatoms, for example from 1 to 3 heteroatoms, selected from O, N and S. When the group contains 2-4 heteroatoms, one may be selected from O, N and S and the remaining heteroatoms may be N.
• Examples of 5 and 6-membered heteroaromatic groups include pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, furyl, thienyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
• d ⁇ alkyl refers to an alkyl group having from one to four carbon atoms, in all isomeric forms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert- butyl.
• n-C 1-4 alkyl refers to the unbranched alkyls as defined above.
• C 1 ⁇ aIkOXy refers to a straight chain or branched chain alkoxy (or “alkyloxy”) group having from one to four carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.
• halogen and its abbreviation “halo” refer to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). Where the term “halo” is used before another group, it indicates that the group is substituted by one, two or three halogen atoms.
• haloC 1-4 alkyl refers to groups such as trifluoromethyl, bromoethyl, trifluoropropyl, and other groups derived from refers to groups such as trifluoromethoxy, bromoethoxy, trifluoropropoxy, and other groups derived from C 1-4 alkoxy groups as defined above.
• 8- to 11 -membered bicyclic group refers to a bicyclic ring system containing a total of 8, 9, 10 or 11 carbon atoms, wherein 1 , 2, 3 or 4 or 5 of the carbon atoms are optionally replaced by a heteroatom independently selected from O, S and N.
• the term includes bicyclic systems wherein both rings are aromatic, as well as bicyclic ring systems wherein one of the rings is partially or fully saturated. Examples of 8- to 1 1- membered bicyclic groups wherein both rings are aromatic include indenyl, naphthyl and azulenyl.
• Examples of 8- to 11-membered bicyclic groups having 1 , 2, 3, 4 or 5 heteroatoms, in which both rings are aromatic include: 6H-thieno[2,3-b]pyrrolyl, imidazo[2,1- b][1 ,3]thiazolyl, imidazo[5,1-b][1 ,3]thiazolyl, [1 ,3]thiazolo[3,2-b][1 ,2,4]triazolyl, indolyl, isoindolyl, indazolyl, benzimidazolyl e.g. benzimidazol-2-yl, benzoxazolyl e.g.
• benzoxazol- 2-yl benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzothienyl, benzofuranyl, naphthridinyl, quinolyl, quinoxalinyl, quinazolinyl, cinnolinyl and isoquinolyl.
• Examples of 8- to 11 -membered bicyclic groups having 1 , 2, 3 , 4 or 5 heteroatoms, in which one of the rings is partially or fully saturated includes dihydrobenzofuranyl, indanyl, tetrahydronaphthyl, indolinyi, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolyl, benzoxazinyl and benzoazepinyl.
• heterocyclyl refers to a 5 or 6-membered monocyclic or 8 to 1 1 -membered bicyclic group wherein 1 , 2, 3, 4 or 5 of the carbon atoms are replaced by a heteroatom independently selected from O, S and N and which is partially or fully saturated.
• heterocyclyl which are fully saturated 5 or 6-membered monocyclic rings include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, isothiazolyl, thiazolyl, tetrahydrofuranyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl, dioxanyl, tetrahydro-2H-pyranyl and dithianyl.
• heterocyclyl groups which are partially saturated 5 or 6-membered monocyclic rings include oxazolinyl, isoaxazolinyl, imidazolinyl, pyrazolinyl, 1 ,2,3,6-tetrahydropyridyl and 3,6-dihydro-2H-pyranyl.
• heterocyclyl groups which are fully saturated 8 to 11 -membered bicyclic rings include decahydroquinolinyl, octahydro-2H-1 ,4-benzoxazinyl and octahydro-IH-cyclopenta- [6]pyridinyl.
• heterocyclyl groups which are partially saturated 8 to 11- membered bicyclic rings include 2,3-dihydro-1 H-indolyl, 1 ,2,3,4-tetrahydroquinolinyl, 1 ,2,3,4-tetrahydroisoquinolinyl and 2,3,4, 5-tetrahydro-1 H-3-benzazepinyl.
• Any of these groups may be attached to the rest of the molecule at any suitable position.
• salt refers to any salt of a compound according to the present invention prepared from an inorganic or organic acid or base, quaternary ammonium salts and internally formed salts.
• Physiologically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent compounds. Such salts must clearly have a physiologically acceptable anion or cation.
• physiologically acceptable salts of the compounds of the present invention include acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, camphorsulfuric, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example benzenesul, in
• R 1 is halogen, cyano, acetyl, trifluoromethyl, trifluoromethoxy.
• R 2 is hydrogen. In another embodiment, R 2 is C 1-4 alkyl (e.g. methyl).
• R 5 is a group selected from: isoxazolyl, 2-pyrrolidinonyl, 1 ,1-dioxido- 2-isothiazolidinyl which is optionally substituted by one or two substituents selected from: halogen, cyano, C 1-2 alkyl (e.g. methyl), haloC ⁇ alkyl (e.g. trifluoromethyl), C 1-2 alkoxy (e.g. methoxy), C 1-3 alkanoyl (e.g. acetyl).
• R 1 is bromo, fluoro, trifluoromethoxy, cyano, hydroxy, chloro, methoxy, tert-butyl, trifluoromethyl.
• R 5 is isoxazolyl, 2-pyrrolidinonyl, -CH 2 -N-pyrrolyl, 1 ,1-dioxido-2-isothiazolidinyl, 2-thienyl, 2-pyridyl, 2-thiazolyl.
• p is 1 or 2.
• R 4 may be optionally substituted phenyl (e.g. phenyl, 4- trifluoromethyl-phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4-tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2- pyridinyl, 2-methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g.
• phenyl e.g. phenyl, 4- trifluoromethyl-phenyl, 3,4-difluorophenyl
• an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline, 8-flu
• pyrimidyl e.g. 5-pyrimidinyl
• an optionally substituted pyridazinyl e.g. 4-pyridazinyl
• an optionally substituted pyrazinyl e.g. 5-methyl-2-pyrazinyl
• oxazolyl e.g. 4-methyl-1 ,3-oxazol-5-yl
• 2-methyl-5-trifluoromethyl-1 ,3-oxazol-4-yl 2-methyl-5-trifluoromethyl-1 ,3-oxazol-4-yl
• an optionally substituted isoxazolyl e.g. 3- methyl-5-isoxazolyl
• an optionally substituted thiazolyl e.g. 2,4-dimethyl-1 ,3-thiazol-5-yl
• an optionally substituted triazolyl e.g. 1 -methyl-1 H-1 ,2,3-triazol-4-yl.
• R 3 is methyl
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IB) as herein defined or a salt thereof.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C ⁇ alkanoyl; and when R 1 is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• R 4 examples include an optionally substituted phenyl (e.g. phenyl, 4-trifluoromethyl- phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4- tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2-pyridinyl, 2- methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g.
• phenyl e.g. phenyl, 4-trifluoromethyl- phenyl, 3,4-difluorophenyl
• an optionally substituted bicyclic group such as quinolinyl (e.g. 2-methylquinoline
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IC) as herein defined or a salt thereof.
• a mammal e.g. human
• IC formula
• a compound of formula (IC) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C 1-4 alkyl, fluoroC 1-4 alkyl, C 1-4 alkoxy, fluoroC 1-4 alkoxy, and when Ri is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• Examples of R 4 include those defined previously for compounds (IB).
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (ID) as herein defined or a salt thereof.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C 1-4 alkyl, fluoroC 1-4 alkyl, d -4 alkoxy, fluoroC 1-4 alkoxy, C 1-4 alkanoyl; and when Ri is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• Examples of R 4 include those defined previously for compounds (IB).
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IE) as herein defined or a salt thereof. Also provided is a compound of formula (IE) or a salt thereof for use in the treatment of a somatoform disorder and premature ejaculation.
• a mammal e.g. human
• G corresponds to 2-pyridyl (Compounds (IEi)) and in another embodiment to 3-pyridyl (Compounds (IE 2 )), as illustrated below:
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C 1-4 alkyl, fluoroC 1-4 alkyl, C 1- 4 alkoxy, fluoroC ⁇ alkoxy, C 1-4 alkanoyl; and when Ri is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• R 4 examples include those defined previously for compounds (IB).
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IF) as herein defined or a salt thereof.
• a mammal e.g. human
• an effective amount of a compound of formula (IF) as herein defined or a salt thereof comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IF) as herein defined or a salt thereof.
• a compound of formula (IF) or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C ⁇ alkyl, fluoroC ⁇ alkyl, C 1-4 alkoxy, fluoroC ⁇ alkoxy, C ⁇ alkanoyl; and when Ri is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• R 4 examples include those defined previously for compounds (IB).
• Compounds of formula (IE)' correspond to the stereochemical isomers of compounds of formula (IE) as above defined, enriched in configuration (1 R, 5R) or (1 R, 5S) depending on the presence of a 2-pyridine ring.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IB)' as herein defined or a salt thereof.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d ⁇ alkyl, fluoroC ⁇ alkyl, C 1-4 alkoxy, fluoroC 1-4 alkoxy, C 1 . 4 alkanoyl; and when Ri is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• R 4 examples include optionally substituted phenyl (e.g. phenyl, 4-trifluoromethyl-phenyl, 3,4-difluorophenyl), an optionally substituted bicyclic group such as quinolinyl (e.g. 2- methylquinoline, 8-fluoro-2-methylquinoline), an optionally substituted pyranyl (e.g. 4- tetrahydro-2H-pyranyl), an optionally substituted pyridinyl (e.g. 3-methyl-2-pyridinyl, 2- methyl-3-pyridinyl, 3-pyridinyl, 2-methyl-6-trifluoromethyl-3-pyridinyl), an optionally substituted pyrazolyl (e.g.
• phenyl e.g. phenyl, 4-trifluoromethyl-phenyl, 3,4-difluorophenyl
• an optionally substituted bicyclic group such as quinolinyl (e.g. 2- methylquinoline,
• 5-chloro-2- thienyl an optionally substituted oxazolyl (e.g. 4-methyl-1 ,3-oxazol-5-yl, 2-methyl-5- trifluoromethyl-1 ,3-oxazol-4-yl), an optionally substituted isoxazolyl (e.g. 3-methyl-5- isoxazolyl), an optionally substituted thiazolyl (e.g. 2,4-dimethyl-1 ,3-thiazol-5-yl), an optionally substituted triazolyl (e.g. 1-methyl-1 H-1 ,2,3-triazol-4-yl).
• oxazolyl e.g. 4-methyl-1 ,3-oxazol-5-yl, 2-methyl-5- trifluoromethyl-1 ,3-oxazol-4-yl
• isoxazolyl e.g. 3-methyl-5- isoxazolyl
• an optionally substituted thiazolyl e.g. 2,4-d
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IC)' as herein defined or a salt thereof.
• a compound of formula (IC)' or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d ⁇ alkyl, fluoroC ⁇ alkyl, d. 4 alkoxy, fluoroC ⁇ alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• R 4 include those defined previously for compounds (IB)'.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (ID)' as herein defined or a salt thereof.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C ⁇ alkyl, fluoroC 1-4 alkyl, Ci -4 alkoxy, fluoroC 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• Examples of R 4 include those defined previously for compounds (IB)'.
• a new use of a stereochemical isomer enriched in the (1 S,5R) configuration or (1 R.5R) configuration of formula (IE)' or a salt thereof is provided, wherein G is 2-pyridyl or 3-pyridyl and R 1 , p, R 3 and R 4 are as defined for formula (I):
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation in a mammal.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IE)' as herein defined or a salt thereof.
• a mammal e.g. human
• IE formula
• IE formula (IE)' or a salt thereof for use in the treatment of a somatoform disorder as defined above and premature ejaculation.
• G corresponds to 2-pyridyl (Compounds (IE 1 )') and in another embodiment to 3-pyridyl (Compounds (IE 2 )'), as illustrated below:
• the configuration will then change depending on the type of pyridine ring, as mentioned above.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 11-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, d ⁇ alkyl, fluoroC 1-4 alkyl, C 1 .
• R 4 alkoxy, fluoroC 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such Ri is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• R 4 include those defined previously for compounds (IB)'.
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (IF)' as herein defined or a salt thereof.
• a mammal e.g. human
• an effective amount of a compound of formula (IF)' as herein defined or a salt thereof.
• R 3 is methyl.
• R 4 may be phenyl, heterocyclyl, 5- or 6- membered heteroaromatic group or a 9- to 1 1-membered bicyclic group, any of which is optionally substituted by 1 , 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, C ⁇ alkyl, fluoroC ⁇ alkyl, C 1-4 alkoxy, fluoroC 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1 , such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule.
• R 4 include those defined previously for compounds (IB)'.
• Certain of the compounds of the invention may be used as acid addition salts with less than one, or one or more equivalents of the acid.
• the present invention includes within its scope the use of all possible stoichiometric and non-stoichiometric forms.
• Salts may also be prepared from other salts of the compound of formula (I) using conventional methods.
• formulations used in the invention are applied in pharmaceutically acceptable amounts and in pharmaceutically acceptable compositions.
• Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic ingredients.
• an effective amount means that amount necessary to delay the onset of, inhibit the progression of, halt altogether the onset or progression of or diagnose the particular condition being treated.
• an effective amount for treating an obsessive compulsive spectrum disorder will be that amount necessary to inhibit mammalian symptoms of the particular obsessive compulsive spectrum disorder in-situ.
• effective amounts will depend, of course, on the particular condition being treated; the severity of the condition; individual patient parameters including age, physical condition, size and weight; concurrent treatment; frequency of treatment; and the mode of administration. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
• a minimum dose be used, that is, the lowest safe dosage that provides appropriate relief of symptoms. Dosage may be adjusted appropriately to achieve desired drug levels, locally or systemically.
• a variety of administration routes are available. The particular mode selected will depend of course, upon the particular drug selected, the severity of the disease state(s) being treated and the dosage required for therapeutic efficacy.
• the methods of this invention may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects.
• modes of administration include oral, rectal, sublingual, topical, nasal, transdermal or parenteral routes.
• parenteral includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous routes are preferred.
• compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
• compositions suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active compound.
• Other compositions include suspensions in aqueous liquors or nonaqueous liquids such as a syrup, an elixir, or an emulsion.
• Other delivery systems can include time- release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the active compounds of the invention, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art.
• the present invention provides a new use of a compound of formula (I) selected from the following group consisting of:
• a still further aspect of the invention provides a method of treating a somatoform disorder as defined above and premature ejaculation which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) selected from the list of compounds above or a salt thereof. Also provided is a compound of formula (I) selected from the list of compounds above cited or a salt thereof for use in the treatment of a somatorm disorder as defined above and premature ejaculation.
• Sydeham's chorea torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculationin a mammal.
• a still further aspect of the invention provides a method of treating of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions,
• Sydeham's chorea torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of formula (I) selected from the list of compounds above and salts thereof.
• a compound of formula (I) selected from the list of compounds above, and salts thereof, for use in the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation.
• a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and premature ejaculation.
• a somatoform disorder is binge eating.
• VCD Experimental vibrational circular dichroism
• NBS N-bromosuccinimide
• Vitride "Red-AI®”
• HOBt 1-hydroxybenzotriazole
• EtOAc ethyl acetate
• Et 2 O dietyl ether
• DMF N,N'-dimethylformamide
• MeOH methanol
• TFA trifluoroacetic acid
• tetrahydrofuran tetrahydrofuran
• IPA isopropanol
• TEA triethylamine
• DCC 1 ,3- dicyclohexylcarbodiimide
• SCX strong cation exchanger
• TIc refers to thin layer chromatography on silica plates
• dried refers to a solution dried over anhydrous sodium sulphate
• r.t. (RT) refers to room temperature
• Rt retention time
• DMSO dimethyl sulfoxide.
• Triflouroacetic anhydride (0.21 mL) was added to a solution of 4-[3-azabicyclo[3.1.0]hex- 1-yl]benzonitrile (280 mg, prepared in analogy to the method described in Preparation 5), and triethylamine (0.25 mL) in dichloromethane (15 mL) at O 0 C.
• the reaction mixture was allowed to warm to room temperature over 2h, then washed with saturated NaHCO 3 , the organic layer dried and evaporated to give 269 mg of the title compound.
• Ethyl-2-chloroacetoacetate (1 wt; 1 eq., 1000 g) was aged with formamide (0.68 vol; ca. 2.8 eq.) and the resulting solution was heated to 120 0 C. After 5 hours the mixture was allowed to cool to room temperature and allowed to age under nitrogen over night. The mixture was treated with NaOH (3 M, 6 vol, reaction moderately exothermic) and stirred at room temperature for 4 hours. Ethyl acetate (6 vol) was added and the phases allowed to separae. The organic layer was discarded while the aqueous was acidified with cone. (32%) aqueous HCI to pH 2 (ca. 2.0 vol). A precipitate started to form.
• the cake was suspended in 1 M aqueous NaOH (13 vol) and heated to 70 0 C for 30 min. After this time, the mixture was cooled to 25 ⁇ 2 0 C and a solid was removed by filtration. The cake was washed with 1 M aqueous NaOH (10 vol). The combined mother liquors were cooled to 0 0 C and acidified to ca. pH 5 with HCI (aqueous, 16%; NOTE: keep temperature while adding HCI below +10 0 C). The suspended product was isolated by filtration washing with water (2x3 vol).
• Milled sodium hydroxide (40 g) was added in small portions to a stirred solution of trimethylsulfoxonium iodide (219 g) in DMSO (anhydrous, 2 I). The resulting mixture was allowed to stir at room temperature for 1.5 h.
• the configuration of the title compound was assigned by comparing its experimental VCD spectrum and observed specific rotation to the data observed for (1 S,5R)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane (see Preparation 48) as the reference sample.
• the assignment of the absolute configuration of the title compound was confirmed by a single crystal X-ray structure obtained from a crystal of (1 S,5R)-1-[4- (trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane, (S)-(+)-mandelic acid salt.
• UV wavelengh range 200-400 nm Analysis time 25 min ret. time (min) % a/a
• the title compound was prepared in 160 mg yield from commercially available methyl 4-fluorophenylacetate (1 g, 6 mmol) following the methods described in preparations 1 , 2, 3, 4, 6.
• the title compound was prepared in 1.25g yield from commercially available methyl 3-chlorophenylacetate (5 g, 27 mmol) following the methods described in preparations 1 , 2, 3, 4, 5.
• the title compound was prepared in 1.2 g yield from commercially available methyl 3-methoxyphenylacetate (5 g, 27.7 mmol) following the methods described in preparations 1 , 2, 3, 4, 5.
• the absolute configuration of the optical isomers was assigned as described for Preparation 18.
• the assignment of the absolute configuration of the title compound was confirmed by a single crystal X-ray structure obtained from a crystal of (1 S,5f?)-1-(4-bromophenyl)-3- azabicyclo[3.1.0]hexane, (S)-(+)-O-acetyl mandelic acid salt.
• Both, analysis based on the known configuration of the (S)(+)-acetyl mandelic acid and on the basis of anomalous dispersion effects confirmed the assignment of the title compound as being (1 S,5R)-1-(4- bromophenyl)-3-azabicyclo[3.1.Ojhexane.
• UV wavelength 285 nm, band width 130 nm
• a DMSO (140 mL) solution of this crude product was added dropwise to a preformed solution of trimethylsulfoxonium iodide (2 eq with respect to component A plus 2 eq with respect to component B) in anhydrous DMSO (412 mL) to which NaH (3 eq with respect to component A plus 2 eq with respect to component B) had been added portionwise.
• the reaction mixture was stirred for 30 min and AcOH (2 eq) was added followed by water.
• the reaction mixture was extracted with Et 2 O and then with EtOAc, the combined organic layers were washed with saturated aqueous NaCI and dried over Na 2 SO 4 .
• the solution was filtered and the filtrate was concentrated in vacuo.
• the crude product obtained was triturated with water and then with cyclohexanes to give the title compound as light brown solid (5.98 g).
• This material was recrystallised 2 times from CH 3 CN (25 mL per g solid) to give 1.57 g of a white solid. This material was then suspended in sodium hydroxide (1 M solution, 1.1 eq) and dichloromethane (100 ml_) and allowed to stir at room temperature until complete dissolution. After separation of the two phases, the aqueous layer was extracted again with dichloromethane. The combined organic layers were washed with sodium hydroxide and then dried over Na 2 SO 4 . Evaporation of solvent in vacuo gave the title compound (874 mg) as colorless liquid.
• the title compound was separated to give the separated enantiomers by preparative chromatography using a chiral column chiralcel AD 10 um, 250 x 21 mm, eluent A: n- hexane; B: isopropanol + 0.1 % isopropyl amine, gradient isocratic 2% B, flow rate 7 mL/min, detection UV at 200-400 nm.
• Retention times given were obtained using an analytical HPLC using a chiral column chiralcel AD 5 um, 250 x 4.6 mm, eluent A: n- hexane; B: isopropanol +0.1% Isopropyl amine, gradient isocratic 2% B, flow rate 1.2 mL/min, detection UV at 200-400 nm.
• Diisopinocampheylborane was prepared following the procedure reported in J. Org. Chem. 1984, 49, 945-947.
• 2-[(1Z)-3-Chloro-1-(chloromethyl)-1-propen-1-yl]-4,4,5,5- tetramethyl-1 ,3,2-dioxaborolane (previously described in Tetrahedron Lett. 1993, 34, 4827-4828) was prepared following the general procedure reported in Tetrahedron Lett. 1989, 30, 2929, using 1 ,4-dichloro-2-butyne. The material thus obtained was further converted following the procedure reported in Synlett 2002, 5, 829-831.
• the title compound was prepared in 480 mg yield (84%) as a colorless oil from 5- [(I R.SS/I S. ⁇ RS ⁇ S-azabicyclotS.I .Olhex-i-yl ⁇ -methyl-I .S-benzothiazole (374 mg) in analogy to the method described in Preparation 40.
• the reaction mixture was heated at 80 0 C for 4 h and the solvent evaporated under vacuum.
• the crude product was treated with diethyl ether and saturated aqueous ammonium chloride solution, the organic phase was washed with brine, dried over sodium sulphate and concentrated under vacuum.
• the crude product was purified by chromatography over silica gel (cyclohexane/ETOAC 8/1 ). The purified product was then dissolved in CH 2 CI 2 (10 ml_) and trifluoroacetic acid was added (4 ml_). After 2 h the reaction mixture was treated with solid sodium carbonate and the solvent evaporated. The residue was treated with water and extracted with CH 2 CI 2 , the organic phase washed with brine, dried over sodium sulphate and evaporated to give the title compound (0.1g, 34%).
• the reaction mixture was heated at 88 0 C for 2 h, and the solvents evaporated under vacuum.
• the crude product was treated with diethyl ether and water, the organic phase washed with brine, dried over sodium sulphate, concentrated under vacuum and extracted twice with ether.
• the solvent was evaporated and the crude product purified by chromatography over silica gel (cyclohexane/ETOAC 8/1 ).
• the recovered product was then dissolved in CH 2 CI 2 (10 mL) and trifluoroacetic acid was added (4 mL). After 3 h the reaction mixture was treated with solid sodium carbonate and the solvent evaporated.
• the residue was treated with water and extracted with CH 2 CI 2 , the organic phase washed with brine, dried over sodium sulphate and evaporated to give the title compound (0.12 g, 45%).
• Example 1 S-IS-US-KIR.SS/IS.SRJ-i ⁇ -MethoxyphenyO-S-azabicyclotS.I.Olhex-S- yl]propyl ⁇ thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methylquinoline hydrochloride
• Example 1 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 2.1 cm, eluent CO 2 containing 20% (ethanol + 0.1% isopropanol), flow rate 25 mL/min, P 194 bar, T 35 0 C, detection UV at 220 nm, loop 1 ml_.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 20% (ethanol + 0.1 % isopropanol), flow rate 2.5 mUmin, P 194 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 2 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel OJ-H, 25 x 2.1 cm, eluent CO 2 containing 12% (ethanol + 0.1 % isopropylamine), flow rate 2.5 mL/min, P 196 bar, T 36 0 C, detection UV at 220 nm, loop 1 ml_.
• Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be 5-[5-( ⁇ 3-[(1R,5S)-1-(4- bromophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl ⁇ thio)-4-methyl-4H-1 ,2,4-triazol-3-yl]-2- methylquinoline.
• (1S.5R)- 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane (see Preparation 48) was used as the reference.
• Enantiomer 2 was assigned as described for Enantiomer 1 to be ⁇ -fS- ⁇ S-KI S.SRJ-i ⁇ -bromophenyO-S-azabicyclolS.I .Olhex-S-yllpropylJthioH- methyl-4/-/-1 ,2,4-triazol-3-yl]-2-methylquinoline.
• Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
• Example 3 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chiralcel OD 10 ⁇ m, 250 x 20 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 35% B, flow rate 7 mLVmin, detection UV at 200-400 nm, CD 230 nm. Retention times given were obtained using an analytical HPLC using a chiral column Chiralcel OD 5 ⁇ m, 250 x 4.6 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 25% B, flow rate 1 mL/min, detection UV at 200-400 nm.
• Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
• Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be 5-[5-( ⁇ 3-[(1 S,5ft)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl ⁇ thio)-4-methyl-4/-/-1 ,2,4-triazol-3-yl]-2- methylquinoline.
• Enantiomer 2 was assigned as described for Enantiomer 1 to be 5-[5-( ⁇ 3-[(1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hex-3-yl]propyl ⁇ thio)-4- methyl-4H-1 ,2,4-triazol-3-yl]-2-methylquinoline.
• Enantiomer 1 showed fpKi (D3) > 0.6 log-unit higher than Enantiomer 2.
• Example 5 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) as described in Example 1 but applying a pressure of 200 bar instead of 194 bar.
• Enantiomer 2 showed fpKi (D3) > 0.9 log-unit higher than Enantiomer 1.
• Example 6 4-[(1 R.5S/1 S,5R)-3-(3- ⁇ [4-Methyl-5-(2-methylquinolin-5-yl)-4tf-1 ,2,4-triazol-3- yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hex-1-yl]benzonitrile hydrochloride
• Example 7 4-[(1 R.5S/1 S,5R)-3-(3- ⁇ [4-Methyl-5-(2-methylquinolin-5-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hex-1 -yl]phenol hydrochloride
• Example 8 (1 R.5S/1 S,5/?)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-1-phenyl-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 9 (1 /?,5S/1 S,5/?)-1 -(4-Bromophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol- 5-yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 9 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel AS-H, 25 x 2.1 cm, eluent CO 2 containing 11% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0 C, detection UV at 220 nm, loop 2 ml_.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 10% (ethanol + 0.1 % isopropyilamine), flow rate 2.5 mL/min, P 199 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be (IS, 5 R)-I -(4- bromophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane. (7R,5S)-1-(4-Bromophenyl)-3- azabicyclo[3.1.0]hexane (compare Preparation 32) was used as the reference.
• Enantiomer 2 was assigned as described for Enantiomer 1 to be (1R,5S)-1-(4-bromophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4- triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 10 (1 R.5S/1 S,5R)-1 -(4-fert-Butylphenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 11 (1 /?,5S/1 S, 5/?)-1 -(3,4-Dichlorophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 11 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 194 bar, T 36 0 C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 190 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 0.5 log-units higher than Enantiomer 2.
• Example 12 (1R.5S/1 S,5R)-1-(4-methoxyphenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1, 3- oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 12 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 9% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0 C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 8% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 190 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 13 (1 /?,5S/1 S,5R)-1 -[4-(5-methyl-3-isoxazolyl)phenyl]-3-(3- ⁇ [4-methyl-5-(4- methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 15 (1 S,5/?)-3-(3- ⁇ [4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4/7-1 ,2,4-triazol-3- yl]thio ⁇ propyl)-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 16 (1 R.5S/1 S,5R)-1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3- ⁇ [4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]- hexane hydrochloride
• Example 16 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chiralpak AD 10 ⁇ m, 250 x 21 mm, eluent A: n-hexane; B: isopropanol + 0.1% isopropyl amine, gradient isocratic 9% B, flow rate 7 mL/min, detection UV at 200-400 nm.
• Retention times given were obtained using an analytical HPLC using a chiral column Chiralpak AD-H 5 ⁇ m, 250 x 4.6 mm, eluent A: n-hexane; B: isopropanol, gradient isocratic 15% B, flow rate 0.8 mL/min, detection UV at 200-400 nm.
• Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
• Example 17 (1 R,5S ⁇ S,5fl)-3-(3- ⁇ [4-Methyl-5-(4-methyM ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-1-[3-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 17 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 10% (ethanol + 0.1 % isopropanol), flow rate 2.5 mL/min, P 180 bar, T 35 0 C, detection UV at 220 nm, loop 1 mL.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 10% (ethanol + 0.1% isopropanol), flow rate 22 mL/min, P 190 bar, T 36 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 18 (1 R.5S/1 S,5R)-1 -[4-Fluoro-3-(trifluoromethyl)phenyl]-3-(3- ⁇ [4-methyl-5- (4-methyl-1 ,3-oxazol-5-yl)-4W-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]- hexane hydrochloride
• Example 19 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 196 bar, T 36 0 C, detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 190 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 20 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 15% (ethanol + 0.1 % isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0 C 1 detection UV at 220 nm, loop 1 mL Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mL ⁇ in, P 190 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 was assigned using comparative VCD and comparative OR analyses of the corresponding free base to be (1S,5f?)-1-(4- chlorophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3- yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane.
• Enantiomer 2 was assigned as described for Enantiomer 1 to be (1 f?,5S)-1 -(4-chlorophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4tf-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 21 ⁇ 1S.5R/1 /?,5S)-1-(4-Fluorophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3- oxazol-5-yl)-4W-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 21 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 196 bar, T 36 0 C, detection UV at 220 nm, loop 1 ml_.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 6% (ethanol + 0.1% isopropylamine), flow rate 2.5 r ⁇ Umin, P 190 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 22 ( ⁇ S,5R/f/?,5S)-1-(3-Chlorophenyl)-5-methyl-3-(3- ⁇ [4-methyl-5-(4-methyl- 1 ,3-oxazol-5-yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.OJhexane hydrochloride
• Example 22 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 15% (ethanol + 0.1 % isopropylamine), flow rate 22 ml_/min, P 192 bar, T 36 0 C, detection UV at 220 nm, loop 1 ml_.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 15% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 180 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 23 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 22 mL/min, P 192 bar, T 36 0 C, detection UV at 220 nm, loop 1 ml_.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 6% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 190 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 24 (1 S,5fl/f K,5S)-3-(3- ⁇ [4-methyl-5-(4-methyM ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-S-yllthiolpropylJ-i-ia-tmethyloxyJphenyll-S-azabicyclo ⁇ .i .Olhexane hydrochloride
• Example 24 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralcel OJ-H, 25 x 2.1 cm, eluent CO 2 containing 13% (2-propanol + 0.1% isopropylamine), flow rate 22 mL/min, P 200 bar, T 36 0 C, detection UV at 220 nm.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralcel OJ-H, 25 x 0.46 cm, eluent CO 2 containing 13% (2-propanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 180 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 29 ⁇ -IS-KS- ⁇ IS.SR/tR.SSJ-i ⁇ -ChlorophenyO-S-azabicycloIS.I .Olhex-S- yl]propyl ⁇ thio)-4-methyl-4H-1,2,4-triazol-3-yl]-2-methylquinoline hydrochloride
• Example 29 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 25% (ethanol + 0.1 % isopropylamine), flow rate 22 mL/min, P 199 bar, T 36 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 30 (1S,5R/1 K,5S)-3-(3- ⁇ [4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 , 2,4- triazol-3-yl]thio ⁇ propyl)-1- ⁇ 4-[(trifluoromethyl)oxy]phenyl ⁇ -3-azabicyclo[3.1.0]hexane hydrochloride
• Example 30 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chirapak AS-H, 25 x 2 cm, eluent A: n-hexane; B: isopropanol, gradient isocratic 15% B v/v, flow rate 7 mL/min, detection UV at 220 nm. Retention times given were obtained using chiral column Chiracel OD, 25 x 0.46 cm, eluent A: n-hexane; B: isopropanol, gradient isocratic 10% B v/v, flow rate 1 mL/min, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 33 (1 S.5R/1 R,5S)-3-(3- ⁇ [4-Methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-1- ⁇ 4-[(trifluoromethyl)oxy]phenyl ⁇ -3-azabicyclo[3.1. OJhexane hydrochloride
• Example 33 was separated to give the separated enantiomers by semipreparative Supercritical Fluid Chromatography (Gilson) using a chiral column Chiralpak AS-H, 25 x 2.1 cm, eluent CO 2 containing 8% (2-propanol + 0.1% isopropylamine), flow rate 22 mL/min, P 200 bar, T 36 0 C, detection UV at 220 nm.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AS-H, 25 x 0.46 cm, eluent CO 2 containing 8% (2-propanol + 0.1% isopropylamine), flow rate 2.5 mL/min, P 180 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 1 showed fpKi (D3) > 1 log-unit higher than Enantiomer 2.
• Example 34 (1 f?,5S/1 S,5f?)-1-(3-Bromophenyl)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5- yl)-4H-1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hexane hydrochloride
• the title compound was prepared in 23 mg yield as a white slightly hygroscopic solid from (1R,5S/1 S,5R)-1-(3-bromophenyl)-3-azabicyclo[3.1.0]hexane (140 mg) in analogy to the method described in Example 1 and purifying the free base of the title compound by preparative HPLC using a column X Terra MS C18 5 ⁇ m, 100 x19 mm, eluent A: H 2 O+0.1% TFA; B: CH 3 CN+0.1 % TFA, gradient 10% (B) for 1 min, from 10% (B) to 35% (B) in 12 min, flow rate 17 mL/min, detection UV at 200-400 nm.
• Example 35 was separated to give the separated diastereoisomers by semi-preparative HPLC using a chiral column Chirapak AD, 25 x 2 cm, eluent A: n-hexane; B: ethanol ⁇ 0.1% isopropylamine, gradient isocratic 15% B v/v, flow rate 7 ml_/min, UV wavelength range 220-400 nm. Retention times given were obtained using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent A: n-hexane; B: ethanol ⁇ 0.1% isopropylamine, gradient isocratic 17% B v/v, flow rate 1 mL/min, UV wavelength range 200-400 nm.
• Example 36 (1 R.5S/1 S,5R)-1 -[2-Fluoro-5-(trifluoromethyl)phenyl]-3-(3- ⁇ [4-methyl-5-
• Example 36 was separated to give the separated enantiomers by semi-preparative HPLC using a chiral column Chirapak AS-H, 25 x 2 cm, eluent A: n-hexane; B: isopropanol + 0.1 % isopropylamine, gradient isocratic 10% B v/v, flow rate 7 mL/min, detection UV at 220 nm.
• Retention times given were obtained using an analytical Supercritical Fluid Chromatography (Berger) using a chiral column Chiralpak AD-H, 25 x 0.46 cm, eluent CO 2 containing 7% (ethanol + 0.1% isopropylamine), flow rate 2.5 mUmin, P 180 bar, T 35 0 C, detection UV at 220 nm.
• Enantiomer 2 showed fpKi (D3) > 1 log-unit higher than Enantiomer 1.
• Example 37 1 -[4-[(1 K.5S/1 S,5/?)-3-(3- ⁇ [4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hex-1-yl]-2- (methyloxy)phenyl]ethanone hydrochloride
• Example 38 1-[4-[(1R,5S/1S,5R)-3-(3- ⁇ [4-methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H- 1 ,2,4-triazol-3-yl]thio ⁇ propyl)-3-azabicyclo[3.1.0]hex-1 -yl]-2-(methyloxy)phenyl]-1 - propanone hydrochloride
• Example 39 (1 R.5S/1 S,5R)-3-(3- ⁇ [4-Methyl-5-(4-methyl-1 ,3-oxazol-5-yl)-4H-1 ,2,4- triazol-3-yl]thio ⁇ propyl)-1-[2-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane hydrochloride
• Example 40 (1 S,5R)-1 -[2-Fluoro-4-(trif luoromethyl)phenyl]-3-(3- ⁇ [4-methyl-5-(4- methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio ⁇ propyl)-3-a2abicyclo[3.1.0]hexane hydrochloride

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Neurosurgery (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Child & Adolescent Psychology (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Indole Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Liquid Crystal Substances (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (36)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=35098098

Family Applications (1)

Country Status (20)

Cited By (11)

Families Citing this family (13)

Citations (1)

Family Cites Families (15)

• 2005
  • 2005-08-22 GB GBGB0517193.9A patent/GB0517193D0/en not_active Ceased
• 2006
  • 2006-08-21 AT AT06777058T patent/ATE500826T1/de not_active IP Right Cessation
  • 2006-08-21 EA EA200800655A patent/EA016084B1/ru not_active IP Right Cessation
  • 2006-08-21 CA CA002620090A patent/CA2620090A1/en not_active Abandoned
  • 2006-08-21 MX MX2008002564A patent/MX2008002564A/es active IP Right Grant
  • 2006-08-21 US US12/064,119 patent/US20090036461A1/en not_active Abandoned
  • 2006-08-21 BR BRPI0614929-4A patent/BRPI0614929A2/pt not_active IP Right Cessation
  • 2006-08-21 ES ES06777058T patent/ES2361933T3/es active Active
  • 2006-08-21 WO PCT/EP2006/008314 patent/WO2007022980A1/en not_active Ceased
  • 2006-08-21 EP EP06777058A patent/EP1917013B1/de active Active
  • 2006-08-21 DE DE602006020589T patent/DE602006020589D1/de active Active
  • 2006-08-21 KR KR1020087006993A patent/KR101363090B1/ko not_active Expired - Fee Related
  • 2006-08-21 CN CN2006800389371A patent/CN101291669B/zh not_active Expired - Fee Related
  • 2006-08-21 AU AU2006284077A patent/AU2006284077B2/en not_active Ceased
  • 2006-08-21 JP JP2008527394A patent/JP5166267B2/ja not_active Expired - Fee Related
• 2008
  • 2008-02-08 ZA ZA2008/01352A patent/ZA200801352B/en unknown
  • 2008-02-11 IL IL189435A patent/IL189435A0/en unknown
  • 2008-03-11 CR CR9807A patent/CR9807A/es not_active Application Discontinuation
  • 2008-03-11 MA MA30740A patent/MA29774B1/fr unknown
  • 2008-03-12 NO NO20081314A patent/NO20081314L/no not_active Application Discontinuation
• 2012
  • 2012-03-28 US US13/432,359 patent/US20120196910A1/en not_active Abandoned

Patent Citations (1)

Also Published As

Similar Documents

Legal Events